Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Tristan Manalac, 4 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.
3 days ago
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.

Tenofovir bests entecavir for HCC protection in hepatitis B

29 Apr 2021

In patients with chronic hepatitis B (CHB), tenofovir disoproxil fumarate (TDF) appears to perform better than entecavir (ETV) at reducing the risk of hepatocellular carcinoma (HCC) as well as improving survival, especially among those who are naïve to treatment and with underlying cirrhosis, as reported in a study.

This meta-analysis included studies comparing the impact of the two drugs on the risk of HCC in CHB patients. Of the 229 records identified, 17 studies were included in the quantitative analysis. Primary and secondary outcomes were the incidence of HCC and overall survival, respectively. Adjusted results were further evaluated by pooling propensity score-matched cohorts.

Pooled data revealed that patients treated with TDF were significantly less likely to develop HCC (risk ratio [RR], 0.63, 95 percent confidence interval [CI], 0.43–0.93; p=0.024) and die (RR, 0.69, 95 percent CI, 0.57–0.84; p=0.003) compared with those who received ETV.

Likewise, TDF was associated with a markedly lower HCC risk in the subgroups of patients with cirrhosis (RR, 0.69, 95 percent CI, 0.56–0.84) and those naïve to antiviral treatment (RR, 0.59, 95 percent CI, 0.35–0.98).

Finally, among treatment-naïve patients, TDF use resulted in a substantial increase in survival compared with ETV (RR, 0.69, 95 percent CI, 0.52–0.91).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Tristan Manalac, 4 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.
3 days ago
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.